Association of immunotherapy duration with overall survival in advanced non–small cell lung cancer – this study is being released to coincide with a poster presentation at the 2023 ASCO annual meeting

(Press-News.org) About The Study: The findings of this study provide reassurance that for patients with advanced non–small cell lung cancer whose disease is still responding to immune checkpoint inhibitor therapy at two years, stopping therapy and monitoring rather than continuing immunotherapy indefinitely is a reasonable strategy with sustained clinical benefit. 

Authors: Lova Sun, M.D., M.S.C.E., of the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, is the corresponding author. 

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ 

(doi:10.1001/jamaoncol.2023.1891)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: This study is being released to coincide with a poster presentation at the 2023 ASCO Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2023.1891?guestAccessKey=b6d4fbbf-d578-4e83-b9f8-3f8ffd53b54b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060423

END